Showing 2321-2330 of 5909 results for "".
- The Vision Council’s Membership Base to Include Healthcare, Technology, and Contact Lens Companieshttps://modernod.com/news/the-vision-councils-membership-base-to-include-healthcare-technology-and-contact-lens-companies/2482157/The Vision Council has expanded its membership structure to include healthcare, technology, and contact lens companies, according to a company news release. "With guidance from our Board of Directors to ensure that The Vision Council is both reflective of our evolving industry
- Research: AI Has Perfect Detection Rate for Severe Cases of Retinopathy of Prematurity (ROP)https://modernod.com/news/research-ai-has-perfect-detection-rate-for-severe-cases-of-retinopathy-of-prematurity-rop/2482153/New research from Oregon Health & Science University (OHSU) and collaborators reveal that artificial intelligence technology can accurately and independently detect 100% of severe cases of retinopathy of prematurity (ROP). The research was
- Neurolenses Demonstrate Headache Relief in New Studyhttps://modernod.com/news/neurolenses-demonstrate-headache-relief-in-new-study/2482145/Neurolens announced results of a company-sponsored study evaluating the impact of Neurolens prescription lenses on individuals with headaches. The six-item Headache Impact Test (H
- Sandoz Closes Deal to Acquire Ranibizumab Biosimilar Cimerli from Coherushttps://modernod.com/news/sandoz-closes-deal-to-acquire-ranibizumab-biosimilar-cimerli-from-coherus/2482144/Sandoz has completed the acquisition of the US biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences. In January, in a move to pay down debt and focus on its oncology business, Coherus BioSciences entered into an agreement to divest its Cimerli (ranibiz
- Nicox Names New CEO; Restructures Debt to Focus on NCX 470 Pivotal Trialhttps://modernod.com/news/nicox-names-new-ceo-restructures-debt-to-focus-on-ncx-470-pivotal-trial/2482137/Nicox announced this week that its Board of Directors has promoted Gavin Spencer to Chief Executive Officer. He previously served as Executive Vice-President, Chief Business Officer & Head of Corporate Development. Mr. Gavin will be replacing Andreas Segerros, whose mandat
- Optos Celebrates Milestones: 25,000 Devices Installed Globally and Extensive Clinical Publications Achievedhttps://modernod.com/news/optos-celebrates-milestones-25000-devices-installed-globally-and-extensive-clinical-publications-achieved/2482131/Optos announced a dual milestone achievement of over 25,000 devices installed worldwide, and the collection of 2,500 clinical and peer-reviewed studies spanning 235 disease states, acccording to a company news release. "This remarkable double milestone reflects the unwavering
- Ocular Therapeutix Announces Board of Directors and Leadership Updateshttps://modernod.com/news/ocular-therapeutix-announces-board-of-directors-and-leadership-updates/2482128/Ocular Therapeutix announced Board of Directors and leadership updates with the addition of Pravin U. Dugel, MD as Executive Chairman; and the additions of Jeffrey S. Heier, MD, Peter K. Kaiser, MD, and Sanjay Nayak, MBBS, PhD, to the Ocular management
- FDA Gives Green Light to Okyo Pharma for Clinical Trial Design for OK-101 in Neuropathic Corneal Painhttps://modernod.com/news/fda-gives-green-light-to-okyo-pharma-for-clinical-trial-design-for-ok-101-in-neuropathic-corneal-pain/2482109/Okyo Pharma announced that the FDA has cleared OK-101 as its first investigational new drug (IND) application for the treatment of Neuropathic Corneal Pain (NCP). The initial IND submission to FDA proposed an open-label design for the clinical trial. Based on positiv
- Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japanhttps://modernod.com/news/nicox-and-kowa-enter-into-agreement-for-ncx-470-development-and-commercialization-in-japan/2482106/Nicox SA announced the signature of an agreement granting Kowa exclusive Japanese rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop for the lowering of IOP in patients with glaucoma or ocular hypertension. Under the
- Opthea Names New Clinical and Regulatory Leadership Membershttps://modernod.com/news/opthea-names-new-clinical-and-regulatory-leadership-members/2482091/Opthea announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development; and Fang Li, PhD, RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer Frederic Guerard, PharmD,